Evotec SE ADR (NASDAQ: EVO)’s stock price has gone rise by 6.67 in comparison to its previous close of 5.10, however, the company has experienced a 31.72% increase in its stock price over the last five trading days. benzinga.com reported 2024-11-15 that On Thursday, Halozyme Therapeutics, Inc. HALO submitted a non-binding proposal to Evotec SE EVO to acquire the German company for 11.00 euros per share in cash, implying a fully diluted equity value of 2.0 billion euros (around $2.11 billion).
Is It Worth Investing in Evotec SE ADR (NASDAQ: EVO) Right Now?
Company’s 36-month beta value is 1.45.Analysts have differing opinions on the stock, with 2 analysts rating it as a “buy,” 1 as “overweight,” 2 as “hold,” and 1 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for EVO is 277.01M, and currently, short sellers hold a 0.08% ratio of that floaft. The average trading volume of EVO on November 18, 2024 was 159.93K shares.
EVO’s Market Performance
The stock of Evotec SE ADR (EVO) has seen a 31.72% increase in the past week, with a 76.62% rise in the past month, and a 69.47% gain in the past quarter. The volatility ratio for the week is 8.32%, and the volatility levels for the past 30 days are at 3.89% for EVO. The simple moving average for the past 20 days is 32.27% for EVO’s stock, with a 6.48% simple moving average for the past 200 days.
Analysts’ Opinion of EVO
Morgan Stanley gave a rating of “Equal-Weight” to EVO, setting the target price at $6 in the report published on July 29th of the current year.
EVO Trading at 48.84% from the 50-Day Moving Average
After a stumble in the market that brought EVO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -54.67% of loss for the given period.
Volatility was left at 3.89%, however, over the last 30 days, the volatility rate increased by 8.32%, as shares surge +68.94% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +61.90% upper at present.
During the last 5 trading sessions, EVO rose by +31.72%, which changed the moving average for the period of 200-days by -27.61% in comparison to the 20-day moving average, which settled at $4.11. In addition, Evotec SE ADR saw -53.62% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for EVO
Current profitability levels for the company are sitting at:
- -0.24 for the present operating margin
- 0.14 for the gross margin
The net margin for Evotec SE ADR stands at -0.22. The total capital return value is set at -0.11. Equity return is now at value -16.21, with -8.05 for asset returns.
Currently, EBITDA for the company is 24.12 million with net debt to EBITDA at 1.26. When we switch over and look at the enterprise to sales, we see a ratio of 2.06. The receivables turnover for the company is 3.41for trailing twelve months and the total asset turnover is 0.39. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.09.
Conclusion
In a nutshell, Evotec SE ADR (EVO) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
